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Abstract Yeast piD261/Bud32 belongs to the piD261 family of
atypical protein kinases structurally conserved, from Archaea to
human. The disruption of its gene is causative of severely de-
fective growth. Its human homologue, PRPK, interacts with and
phosphorylates the oncosuppressor p53 protein, which is lacking
in yeast. Here we show that on one hand piD261/Bud32 inter-
acts with and phosphorylates human p53 in vitro, on the other
hand PRPK can partially complement the phenotype of yeast
lacking the gene encoding piD261/Bud32. These data indicate
that, despite considerable structural divergence, members of the
piD261 family from distantly related organisms display a re-
markable functional conservation.
* 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Members of the piD261 atypical protein kinase family are
present along the whole evolutionary scale, from Archaea to
human, but not in eubacteria, suggesting that they make up a
primordial branch of the eukaryotic protein kinase superfam-
ily [1]. Consistent with this the human member of the piD261
family, PRPK, occupies the position closest to the origin in
the dendrogram of the human ‘kinome’ [2]. At protein level
the best characterized member of the piD261 family is Sac-
charomyces cerevisiae piD261/Bud32, which has been ex-
pressed as recombinant protein in Escherichia coli and phos-
phorylates a number of acidic proteins in vitro [3,4]. A
mutational analysis of piD261/Bud32 has led to the conclu-
sion that, despite low sequence similarity with the other mem-
bers of the ePK family, the invariant residues representing the
signature of this latter are conserved in piD261/Bud32 as well,
but are embedded in an altered context [5]. In yeast the dis-
ruption of the gene encoding piD261 is causative of severe
growth defects [6], including low survival of cells in stationary
phase, inability of homozygous diploids to enter sporulation
[7] and tendency to undergo random budding (whence the
acronym Bud32) [8].
The only other member of the piD261 family having been
characterized at protein level to some extent is human PRPK
which was cloned from an interleukin-2 activated cytotoxic
T-cell subtraction library and shown to up regulate transcrip-
tional activity of p53 once transfected in COS-7 cells [9].
PRPK binds to and phosphorylates p53 at Ser15 [9], whence
the acronym PRPK (p53 related protein kinase). In yeast
bona ¢de p53 homologue(s) are not present and whether or
not are there in yeast proteins which may surrogate p53 func-
tions is still a matter of debate.
These premises raised the question whether or not piD261/
Bud32 and PRPK play at least partially interchangeable func-
tions, despite their structural similarity that is rather modest
(30% identity). Here we show that indeed piD261/Bud32 in-
teracts with the carboxy-terminal domain of human p53 and
phosphorylates its amino-terminal domain, at Ser15 (the same
as a¡ected by PRPK) and Ser37, while conversely, PRPK
partially restores the normal phenotype of yeast strains where
the gene encoding piD261/Bud32 had been disrupted.
2. Materials and methods
2.1. Yeast strains
W303-1B +/vYGR262c/BUD32 (a/K, ade2-1/ade2-1, his3-11,15/his3-
11,15, leu2-3,112/leu2-3,112, trp1-1/trp1-1, ura3-1/ura3-1, can1-100/
can1-100; BUD32/bud32: :kanMX4) ; W303-1B vYGR262c/BUD32
(Mat a ; ade2-1 ; his3-11,15 ; leu2-3,112 ; trp1-1 ; ura3-1 ; canR ; bud32: :
kanMX4). Yeast Media (YPD, SD) were prepared according to [10];
adenine-limiting medium was prepared by adding adenine 10 mg l31
to SD medium. Media components were from Difco, amino acids
from Sigma.
2.2. Cloning of the PRPK and YGR262c/BUD32 coding sequence
The PRPK and BUD32 coding sequences were inserted in the Bam-
HI/KpnI sites of the centromeric galactose-inducible pYeDP1/8.2 vec-
tor [11], giving the PRPK-pYeDP and BUD32-pYeDP plasmids, re-
spectively. The PRPK coding sequence was ampli¢ed from the
I.M.A.G.E. clone ID 3899629 using the 5P-PRPK (5P-AGCTGTTG-
CGCCGAGGATCCATGGCG-3P) and the 3P-PRPK (5P-TGT-
GGTACCCATACACACATTCTACCC-3P) primers; the BUD32
coding sequence was ampli¢ed from yeast genomic DNA using the
5P-BUD32 (5P-CGCTTGGATCCTTATGACGCAAGAA-3P) and 3P-
BUD32 (5P-TACCCTAGGCATGACGGACATATATACG-3P) prim-
ers, which introduce the restriction sites BamHI and KpnI (under-
lined). The BUD32-pASZ11 plasmid was described elsewhere [Lo-
preiato, R., Facchin, S., Sartori, G., Casonato, S., Ruzzene, M.,
Pinna, L.A., Carignani, G. (2003) A study on functional partners of
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2.3. Phenotype complementation assay
Yeast cells of strain W303-1B vBUD32 contained the BUD32-
pASZ11 (adenine) plasmid: the presence in it of the BUD32 coding
sequence under the control of the BUD32 promoter allows the pro-
tection of yeast cells from the damages due to the deletion of the
BUD32 gene.
The ‘protected’ yeast cells were co-transformed with the pYeDP1/
8.2 [11] plasmid alone and pYeDP1/8.2 plasmids containing the yeast
BUD32 or the human PRPK coding sequences, under the control of
the GAL10 promoter (inducible on galactose medium). The co-trans-
formed cells were ¢rst grown in glucose medium (without adenine to
maintain the plasmidic protection) and then shifted to adenine-limit-
ing galactose medium, which induces the speci¢c loss of the protection
plasmid (evaluable by a red color of colonies) and the overexpression
of the Bud32/piD261 and PRPK proteins. The red colonies, still car-
rying the pYeDP vectors, were grown at 28‡C on galactose selective
medium for 4 days.
2.4. Surface plasmon resonance (SRP) analysis
For the SRP analysis, a BIAcoreX system was used, as described in
[12], with the following modi¢cations. piD261 was covalently immo-
bilized on the surface of a £ow cell in a CM5 sensor chip, to a ¢nal
density of 2600 resonance units (RU), while a £ow cell with no im-
mobilized protein was used as a control. The reported values of ki-
netic data are the mean of three separate experiments, with S.E.M.
values lower than 10%.
2.5. Peptide synthesis
The peptides p53(325^356), p53(361^393), p53(344^376) were syn-
thesized by automatic solid phase procedures. The synthesis were
performed on a 431 model (Applied Biosystems) peptide synthesizer
under conditions described elsewhere [4]. After cleavage with TFA the
peptides were puri¢ed to homogeneity by RP-HPLC on a Waters
prepNova-Pak HR C18 column with a linear gradient of 10% to
45% acetonitrile at 12 ml min31. The molecular weights of the pep-
tides were con¢rmed by mass spectroscopy.
2.6. Expression and puri¢cation of p53 and piD261/Bud32
p53-GST: the bacterial clones of BL21 overexpressing p53-GST
and p53(1^363) were kindly provided by Dr. M. Cordenonsi (Padova,
Italy). The p53-His-tagged truncated forms (p53 1^286, p53 264^393,
p53 287^393, p53 340^393) were kindly provided by Dr. M. Monte-
narh (Homburg, Germany) and were obtained as described in [13,14].
The expression and puri¢cation of His-tagged recombinant piD261/
Bud32 were performed as previously described [5].
2.7. Phosphorylation assay
Phosphorylation of 500^1000 ng of CK2L, p53-GST, p53(v363^
393)-GST, p53(1^286)His-tag, and p53(v340^393)-His-tag by
piD261/Bud32 (200 ng) was performed by incubation at 37‡C with
[Q33P]ATP under conditions described previously [5]. Phosphorylation
of p53(340^393) His-tag by protein kinase CK2 was performed by
incubation under conditions described elsewhere [15]. The reaction
was stopped by addition of gel electrophoresis loading bu¡er and
samples were subjected to sodium dodecyl sulfate^polyacrylamide
gel electrophoresis (SDS^PAGE), with 11% gels. The dried gels
were directly scanned on the Cyclone apparatus (Packard).
2.8. Western blot analysis
Approximately 200 ng of recombinant p53-GST were subjected to
11% SDS^PAGE; proteins were blotted onto PVDF membrane
(Millipore) and detected by using the phospho-p53 antibody anti-
phospho Ser(Ser6, Ser9, Ser15, Ser20, Ser37, Ser46 and Ser392) pur-
chased from Cell Signaling Tech. at a 1000-fold dilution. This reaction
was followed by incubation with a HRP-coupled antibody directed
against the corresponding IgG type of the ¢rst antibody.
2.9. Far-Western blot (FWB) analysis
The overlay method was used to provide evidence of interaction
between piD261/Bud32 and p53 and the protein fragments. Approx-
imately 200 ng of puri¢ed recombinant protein p53-GST, of truncated
forms and 50^100 ng of peptides (as indicated in Fig. 3) were sub-
jected to SDS^PAGE or directly spotted onto nitrocellulose mem-
brane (BioRad). The overlay method was performed as described
elsewhere [12].
3. Results
As shown in Fig. 1 full-size p53 is readily phosphorylated
by piD261/Bud32 with an e⁄ciency comparable to that of
other protein substrates previously used for its characteriza-
tion. A similar phosphorylation is observed if C-terminally
truncated forms of p53, lacking the site a¡ected by CK2
(Ser392), are used as substrates for piD261/Bud32. Consistent
with this a C-terminal fragment of p53 encompassing residues
340 to 393, which is phosphorylated by CK2, is not a¡ected to
any appreciable extent by piD261 (Fig. 1, compare lanes 6
and 7).
To gain information about the p53 residues phosphorylated
by piD261 advantage has been taken of speci¢c anti-phospho-
site antibodies. As shown in Fig. 2, p53 previously phosphor-
ylated by piD261 immunoreacted with anti-phospho Ser15
and phospho Ser37 Ab., but not with a number of antibodies
that recognize other phosphosites. It can be concluded there-
fore that Ser15 (the same also a¡ected by PRPK) and Ser37
are the main targets of piD261. Note that these two phos-
phoacceptors sites appear to be functionally related as they
are targeted by the same set of kinases, notably Chk1, DNA-
PK and ATR.
Full-size p53 also physically interacts with piD261, as
judged from FWB analysis (Fig. 3). No interaction however
is observed between piD261 and the truncated form of p53
lacking its C-terminal region (p53(1^286)). This demonstrates
that distinct structural elements along the sequence of p53 are
responsible for physical interaction with and phosphorylation
by piD261.
In order to map more precisely the C-terminal segment of
Fig. 1. Phosphorylation of full-size and truncated forms of p53 by
piD261 (lanes 3^6) and by CK2 (lane 7). For comparison phosphor-
ylation of L-subunit of CK2 by piD261 (lane 2) and autophosphory-
lation of piD261 alone (lane 1) are also shown. Phosphorylation
was performed and evaluated as described in Section 2.7. Substrate
addition in the incubation medium were: none (lane 1), L-subunit
of CK2 (lane 2), p53-GST (lane 3), p53v364^393 (lane 4), p53(1^
286) (lane 5), p53(340^393) (lanes 6 and 7). The band denoted by
an asterisk in lanes 3 and 4 corresponds to a degradation product
of p53, as judged from its reaction with anti-p53 antibodies (not
shown). The faint bands between CK2L and p53(340^393)in lane 7
were bacterial contaminations of the recombinant p53(340^393)
fragment as they are not detectable in the control without p53(340^
393) (not shown).
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p53 responsible for physical interaction with piD261 a number
of peptides variably encompassing the C-terminal domain of
p53 have been synthesized and probed for their ability to
interact by FWB. As shown in Fig. 3 a clear signal was ob-
served with peptides 264^393, 287^393, 340^393 and 325^356,
but not with peptides 361^393, 387^393 and 344^376. These
data, in conjunction with the observation that at variance
with the truncated form p53(1^286) (which does not interact)
a truncated form with a shorter deletion (p53(1^363)) still
interacts with piD261, map between residues 340 and 355
(within the tetramerization domain) the structural element in-
dispensable for the main contacts.
These conclusions are in substantial agreement with the
outcome of a SRP analysis performed using a sensor chip
with bound piD261 and either full-length p53 or its fragments
as analytes. The sensorgrams presented in Fig. 4 disclose reg-
ular interactions of piD261 with both full-size p53 and its
C-terminal 340^393 fragment but not with p53 having a
C-terminal deletion p53(v287^393). The Kd values calculated
for full-size p53 and its C-terminal fragment (2.3U1036 and
8.5U1037 M, respectively) are consistent with the view that
the main contacts are concentrated into the C-terminal seg-
ment of p53.
The ability of piD261 to interact with and phosphorylate
p53, a typical property of human PRPK, suggests that, de-
spite the lack of bona ¢de p53 homologues in yeast and the
overall modest sequence identity between the two protein ki-
nases, these latter have conserved similar functions. This con-
cept was corroborated by complementation experiments indi-
cating that human PRPK behaves as a functional homologue
of yeast Bud32, i.e. it is able to partially alleviate the slow-
growth phenotype of yeast cells caused by deletion of the
YGR262c/BUD32 gene, which encodes piD261/Bud32. This
result was obtained by overexpressing the PRPK gene in a
yeast strain deleted of the chromosomal copy of the
YGR262c/BUD32 gene (vYGR262c/BUD32). Mutant yeast
cells, ‘protected’ by the presence of a plasmid expressing
wild-type YGR262c/BUD32, were transformed with a
pYeDP1/8.2 expression plasmid containing the human
PRPK gene under the control of the GAL10 promoter and,
in parallel, with the same plasmid containing the yeast
YGR262c/BUD32 gene or with the plasmid without insert.
After loss of the protection plasmid, transformed cells were
grown on galactose medium. Fig. 5 shows that overexpression
of PRPK in vYGR262c/BUD32 yeast cells partially suppresses
their slow-growth phenotype, consistent with a partial conser-
vation of cellular functions between the yeast and human
proteins. This outcome is in apparent contradiction with the
report of Abe et al. [9] claiming that PRPK could not restore
the slow-growth phenotype of YGR262c/BUD32 disrupted
yeast. This discrepancy may be due to the di¡erent experimen-
tal procedures used in the two experiments.
4. Discussion
Our results show that two members of the atypical protein
kinase family piD261, present in distantly related organisms
such as yeast and human, display, despite considerable struc-
tural divergence, a remarkable functional conservation.
Fig. 2. Mapping the p53 residues phosphorylated by piD261. Identi-
cal aliquots of p53 phosphorylated by incubation with ATP-Mn2þ
and piD261 and resolved by SDS^PAGE (see Section 2.7) were im-
munodetected either with anti-p53 antibodies or with antibodies
that speci¢cally recognize individual phosphoresidues, as indicated
(for details see Section 2.8).
Fig. 3. Mapping the p53 region interacting with piD261 by FWB
analysis. The following (poly)peptides were either run on gel electro-
phoresis and trans-blotted to nitrocellulose membrane (upper panels)
or directly spotted on nitrocellulose (lower panel): full-size p53
(lanes 1 and 4), p53(1^363) (lanes 2 and 5), p53(1^286) (lanes 3 and
6), p53(264^393) (lanes 7 and 9), p53(287^393) (lanes 8 and 10),
p53(325^356) (spot 13), p53(340^393) (spot 14), p53(361^393) (spot
15), p53(387^393) (spot 16), p53(344^376) (spot 17). The lanes/spots
were overlayed with a solution containing or not containing
piD261, as indicated. After extensive washing bound piD261 was re-
vealed by immunoreaction with speci¢c anti-piD261 Abs as detailed
in Section 2.9. Electrophoretic runs were either in 11% SDS^PAGE
(lanes 1^6), or 18% SDS^PAGE (lanes 7^10).
Fig. 4. Analysis of piD261/p53 interaction by SRP signal. Shown are representative sensorgrams (time course of the SRP signal) obtained with
the SRP sensor system BIAcoreX, by injection of p53 and its deletion mutants, at the indicated concentrations, over a sensor surface where
piD261 was covalently immobilized. The responses shown are the di¡erences (RU) obtained by subtraction of the signal detected over a control
surface (without piD261). The arrows mark the start of the injections; the regeneration step is indicated by the asterisk (*).
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Yeast piD261/Bud32 and human PRPK, which share an
overall identity of 32%, have both been shown to phosphor-
ylate acidic substrates in vitro [4,9] ; also, PRPK interacts with
and phosphorylates, both in vitro and in vivo, the tumor
suppressor gene product p53 [9]. Despite p53 having no struc-
tural homologue in yeast, overexpression of human p53 (as
well as of other apoptotic inducers) leads to growth arrest
both in S. cerevisiae [16] and in Schizosaccharomyces pombe
[17], where the protein is phosphorylated at the same sites as
in mammalian cells. This and other observations indicate the
presence in yeast of machinery able to promote the basic steps
of apoptosis [18]. Mammalian p53 can also function in yeast
as a transcription factor in the presence of p53-speci¢c pro-
moters, and this has allowed the identi¢cation of yeast pro-
teins that functionally interact with p53, such as NuA4, a
multisubunit HAT complex, probably present also in animals,
involved in transcription regulation and essential for cell cycle
progression [19^21].
We demonstrate here that yeast piD261/Bud32 has con-
served the property of human PRPK to interact with and
phosphorylate p53 at Ser15, an event that leads, in answer
to DNA damage, to p53 stabilization and increased activity.
The yeast protein phosphorylates p53 at Ser15 and at Ser37,
while its interaction with p53 has been mapped to the C-ter-
minal region of the protein, in particular to a stretch encom-
passing residues 340^355, which are included in the tetrame-
rization domain and partially overlap the nuclear export
sequence.
On the other hand human PRPK must functionally interact
with some yeast proteins, as it signi¢cantly alleviates the slow-
growth phenotype caused by the absence of piD261/Bud32. It
should be noted in this respect that piD261/Bud32 shares with
PRPK nuclear localization, despite the fact that it lacks a
bipartite nuclear localization motif (Lopreiato et al., as noted
in Section 2.2), which is present in the PRPK molecule [9].
Since the only known physiological substrate of PRPK is p53,
which is absent in yeast, the ability of the human protein to
partially complement the mutant phenotype due to the dele-
tion of the yeast YGR262c/BUD32 gene indicates that PRPK
is able to phosphorylate and/or to interact with one or more
of the physiological substrate/partners(s) of piD261/Bud32. It
should be noted that piD261/Bud32 associates with a variety
of proteins, as disclosed by a recent yeast proteome analysis
[22] and by a 2-hybrid system scrutiny (Lopreiato et al. as
noted in Section 2.2). It will be interesting to investigate these
interactions at molecular level, and to see if PRPK also inter-
acts with (some of) the protein partners of piD261/Bud32.
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Fig. 5. Complementation of the slow-growth phenotype of
vYGR262c/BUD32 yeast cells by human PRPK. vYGR262c/BUD32
yeast cells transformed with plasmids pYeDP1/8.2, piD261-pYeDP1/
8.2 or PRPK-pYeDP1/8.2 were grown until stationary phase in ga-
lactose liquid medium to induce overexpression of the gene inserted
in the plasmid. Cultures were then spotted in serial dilutions (1/10,
1/100, 1/1000) on selective galactose solid medium and growth was
observed after 4 days of incubation at 28‡C. It is possible to ob-
serve that overexpression of PRPK partially restores the phenotype
of vYGR262c/BUD32 yeast cells.
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